Inactive Instrument

Morison PLC

MORI.N0000

LK0091N00005

Morison PLC Appoints Sanjit Singh Lamba as Independent Non-Executive Director, Effective September 1, 2020

July 09, 2020

Hemas Corporate Services (Pvt) Ltd. announced that Mr. Sanjit Singh Lamba has been appointed to the board of directors of Morison PLC as an independent non-executive director, effective September 1, 2020. Sanjit is an astute business executive with cross functional experience in diverse functions with over 31 years of proficiency in the pharmaceutical industry.

Latest news about Morison PLC

Morison Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-22	CI
Morison Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-23	CI
Morison PLC Appoints Sanjit Singh Lamba as Independent Non-Executive Director	20-09-03	CI
Morison plc Reports Earnings Results for the First Quarter Ended June 30, 2020	20-08-08	CI
Morison PLC Appoints Sanjit Singh Lamba as Independent Non-Executive Director, Effective September 1, 2020	20-07-09	CI
Morison PLC Announces Retirement of Steven Mark Enderby as Non Independent Non Executive Director, Effective September 30, 2020	20-06-24	CI
Morison plc Reports Earnings Results for the Full Year Ended March 31, 2020	20-05-29	CI
Morison plc Reports Earnings Results for the Third Quarter Ended December 31, 2019	20-02-12	CI
Morison PLC Reports Earnings Results for the Second Quarter Ended September 30, 2019	19-10-25	CI
Morison plc Reports Earnings Results for the First Quarter Ended June 30, 2019	19-07-23	CI
Morison plc Reports Earnings Results for the Fourth Quarter Ended March 31, 2019	19-05-17	CI
Morison plc Reports Earnings Results for the Third Quarter Ended December 31, 2018	19-01-25	CI
Morison PLC Announces Company and Group Earnings Results for the Second Quarter and Six Months Ended September 30, 2018	18-11-05	CI
Morison PLC Appoints Ahmed Zalmi Fazeel as a Non-Independent Non-Executive Director	18-09-03	CI
Ravindra Fernando Resigns from the Board of Directors of Morison plc	18-06-03	CI
Morison PLC Reports Group and Company Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2018	18-05-24	CI
Morison plc Announces Interim Dividend for Fiscal 2018, Payable on March 29, 2018	18-03-09	CI
Morison PLC Reports Group and Company Earnings Results for the Third Quarter and Nine Months Ended December 31, 2017	18-01-26	CI
Morison PLC Appoints Kasturi Chellaraja Wilson as Non-Independent Non-Executive Director	18-01-04	CI
J. L. Morison Son & Jones PLC Reports Audited Group and Company Earnings Results for the First Quarter Ended June 30, 2017	17-08-01	CI
J. L. Morison Son & Jones PLC Reports Group and Company Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2017	17-05-16	CI
J. L. Morison Son & Jones PLC Proposes Final Dividend for the Fiscal Year 2017 Payable on July 4, 2017	17-05-16	CI
J. L. Morison Son & Jones PLC Announces Interim Dividend for Financial Year 2016-2017 Payable on March 28, 2017	17-03-08	CI
J. L. Morison Sons & Jones PLC Reports Group and Company Earnings Results for the Third Quarter and Nine Months Ended December 31, 2016	17-02-13	CI
J.L. Morison Sons & Jones PLC Announces the Resignation of Asoka Abeyewardene as Independent Non-Executive Director	16-11-24	CI

Chart Morison PLC

Duration

Period

More charts

Company Profile

Morison PLC., formerly J.L. Morison Son & Jones (Ceylon) PLC, is a Sri Lanka-based pharmaceutical manufacturer. In addition to manufacturing pharmaceutical and over-the-counter (OTC) products, the Company is also engaged in importing and distribution of healthcare and consumer products. It is engaged in the trading in manufacturing, importing and distribution of pharmaceuticals, medical aid, hair care products, diagnostics reagent and equipment and other consumer products. The Company's OTC and consumer category includes brands, such as Morison's Lacto Calamine, Morison's Gripe Mixture and Valmelix Cough Syrup.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B
PFIZER, INC.	-0.45%	162B

Other Pharmaceuticals